- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 10.10 2016 Inducement Plan
- 10.11 2016 Inducement Plan Option Certificate
- 10.21 Sabella Employment Agreement Amendment
- 10.24 Blank Separation Agreement
- 10.25 Blank Consulting Agreement and Schedule #1
- 10.27 Gesser Offer Letter
- 10.28 Belloff Offer Letter
- 10.51 Catalent Amendment No. 1
- 10.52 Catalent Amendment No. 2
- 21 EX-21
- 23 EX-23
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-248738) of Acorda Therapeutics, Inc., |
| (2) | Registration Statement (Form S-3 No. 333-248728) of Acorda Therapeutics, Inc., |
| (3) | Registration Statement (Form S-3 No. 333-239519) of Acorda Therapeutics, Inc., |
| (4) | Registration Statement (Form S-3 No. 333-235929) of Acorda Therapeutics, Inc., |
| (5) | Registration Statement (Form S-8 No. 333-233177) pertaining to the 2019 Employee Stock Purchase Plan of Acorda Therapeutics, Inc., |
| (6) | Registration Statement (Form S-8 No. 333-131846) pertaining to the 1999 Employee Stock Option Plan and the 2006 Employee Incentive Plan of Acorda Therapeutics, Inc., |
| (7) | Registration Statement (Form S-8 Nos. 333-149726, 333-158085, 333-164626, 333-174785, 333-179906, 333-187091, 333-194375, and 333-202525) pertaining to the 2006 Employee Incentive Plan of Acorda Therapeutics, Inc., |
| (8) | Registration Statement (Form S-8 No. 333-210813) pertaining to the 2016 Inducement Plan of Acorda Therapeutics, Inc., and |
| (9) | Registration Statement (Form S-8 Nos. 333-206346, 333-212917, and 333-226692) pertaining to the 2015 Omnibus Incentive Compensation Plan of Acorda Therapeutics, Inc. |
of our reports dated March 18, 2022, with respect to the consolidated financial statements of Acorda Therapeutics, Inc. and subsidiaries and the effectiveness of internal control over financial reporting of Acorda Therapeutics, Inc. and subsidiaries included in this Annual Report (Form 10-K) of Acorda Therapeutics, Inc. for the year ended December 31, 2021.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 18, 2022